Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin for Podocyte Disease
NCT00098020Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2004
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isotretinoin in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and Collapsing glomerulopathy (CG), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Change in Proteinuria at Week 24 From Baseline. Started Nov 2004; status: completed.
02
Drugs
isotretinoin
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)Collapsing glomerulopathy (CG)
Beyond the preview
Go deeper on NCT00098020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098020.